论文部分内容阅读
目的探讨肺耐药蛋白(LRP)基因在非小细胞肺癌(NSCLC)气管镜活检组织或淋巴结活检组织中的表达与其临床疗效的关系。方法应用免疫组织化学S-P技术对19例非小细胞肺癌气管镜活检组织和28例肺癌转移的淋巴结活检组织进行LRP表达水平的检测,并观察其经NP方案化疗2个周期后的临床疗效。结果非小细胞肺癌LRP的表达阳性率为61.70%;在肺腺癌和肺鳞癌中的表达阳性率分别为76.92%和42.86%;LRP在两组间的表达有显著性差异(P<0.05)。LRP表达水平在TNM分期中差异无显著性(P>0.05);经2个周期标准NP方案化疗后总有效率为42.55%,其中LRP表达阳性和阴性的临床有效率分别为24.14%和72.22%,两组间存在显著性差异(P<0.05)。结论LRP在非小细胞肺癌中存在不同程度的表达,阳性者化疗疗效明显高于阴性者。
Objective To investigate the relationship between the expression of lung resistance protein (LRP) gene in biopsies of non-small cell lung cancer (NSCLC) bronchial biopsy and lymph node biopsy and its clinical efficacy. Methods The immunohistochemical S-P technique was used to detect the expression of LRP in 19 cases of non-small cell lung cancer biopsy and 28 cases of lung cancer metastatic lymph node biopsy, and to observe its clinical efficacy after 2 cycles of NP regimen chemotherapy. Results The positive rate of LRP expression in non-small cell lung cancer was 61.70%. The positive rates of LRP in lung adenocarcinoma and squamous cell lung cancer were 76.92% and 42.86%, respectively. The expression of LRP was significantly different between the two groups (P <0.05 ). The total effective rate of LRP expression in TNM staging was no significant difference (P> 0.05). After 2 cycles of standard NP regimen chemotherapy, the total effective rate was 42.55%, the clinical effective rate of LRP expression positive and negative were 24.14% and 72.22% , There was a significant difference between the two groups (P <0.05). Conclusion LRP expression in non-small cell lung cancer to varying degrees, the positive effect of chemotherapy was significantly higher than the negative.